Search
Adefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedAdefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective ag...
Tebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigational[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … to be approved by the FDA.
Tirasemtiv
go.drugbank.com/drugs/DB12209InvestigationalTirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and Amyotrophic Lateral Sclerosis.
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONProducts: ACETILCISTEINA EGRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141] … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
Pitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalFDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] Etranacogene dezaparvovec was approved by the FDA in November 2022 for the treatment of select patients with hemophilia B, becoming the first gene therapy approved for this indication.
Ammonium chloride
go.drugbank.com/drugs/DB06767ApprovedInvestigationalVet approvedAmmonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.
Mixtures: K.B. SYRUP, COUGH - EN